NasdaqGS - Delayed Quote • USD
BioNTech SE (BNTX)
At close: May 13 at 4:00 PM EDT
Pre-Market: 9:05 AM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 9 | 12 | 13 |
| Avg. Estimate | -2.18 | -0.87 | -2.16 | -2.3 |
| Low Estimate | -3.61 | -3.35 | -4.45 | -5.41 |
| High Estimate | -1.25 | 0.81 | -0.7 | 0.44 |
| Year Ago EPS | -0.83 | 0.73 | 4.12 | -2.16 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 13 | 13 |
| Avg. Estimate | 174.09M | 726.35M | 2.91B | 3B |
| Low Estimate | 66M | 270.32M | 2.37B | 1.79B |
| High Estimate | 463.04M | 1.31B | 3.33B | 3.98B |
| Year Ago Sales | -- | -- | 4.11B | 2.91B |
| Sales Growth (year/est) | -- | -- | -29.30% | 3.20% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -1.01 | -0.1 | 2.61 | -1.17 |
| EPS Actual | -0.83 | 0.73 | 2.05 | -1.41 |
| Difference | 0.18 | 0.83 | -0.56 | -0.24 |
| Surprise % | 17.80% | 830.00% | -21.50% | -20.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -2.18 | -0.87 | -2.16 | -2.3 |
| 7 Days Ago | -2.15 | -0.67 | -2.28 | -1.71 |
| 30 Days Ago | -1.88 | -0.52 | -1.59 | -1.39 |
| 60 Days Ago | -1.76 | -0.65 | 0.68 | 0.96 |
| 90 Days Ago | -1.91 | -0.43 | 1.05 | 1.09 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 2 | 1 | 3 | 1 |
| Up Last 30 Days | 5 | 2 | 9 | 7 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | 1 | -- | -- |
Growth Estimates
| CURRENCY IN USD | BNTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -162.70% | -- | -- | 8.30% |
| Next Qtr. | -219.20% | -- | -- | 11.90% |
| Current Year | -152.40% | -- | -- | 5.60% |
| Next Year | -6.50% | -- | -- | 13.00% |
| Next 5 Years (per annum) | -34.03% | -- | -- | 11.05% |
| Past 5 Years (per annum) | -35.55% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | Evercore ISI Group: In-Line | 5/14/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 5/8/2024 |
| Maintains | TD Cowen: Hold to Hold | 5/7/2024 |
| Maintains | BMO Capital: Outperform to Outperform | 5/7/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/17/2024 |
| Maintains | UBS: Neutral to Neutral | 3/27/2024 |
Related Tickers
MRNA Moderna, Inc.
125.67
+7.13%
VRTX Vertex Pharmaceuticals Incorporated
429.93
+1.69%
INO Inovio Pharmaceuticals, Inc.
11.36
+6.67%
VXRT Vaxart, Inc.
0.8200
+16.31%
REGN Regeneron Pharmaceuticals, Inc.
976.96
+0.32%
CVAC CureVac N.V.
2.9700
+2.06%
NTLA Intellia Therapeutics, Inc.
25.42
+3.92%
NVAX Novavax, Inc.
13.11
+47.64%
CRSP CRISPR Therapeutics AG
55.65
+8.76%
IOVA Iovance Biotherapeutics, Inc.
10.88
-0.78%